Does Targeting CPP at CPPopt Actually Improve Cerebrovascular Reactivity? A Secondary Analysis of the COGiTATE Randomized Controlled Trial

Erta Beqiri,Jeanette Tas,Marek Czosnyka,Ruud C. R. van Kaam,Joseph Donnelly,Roel H. Haeren,Iwan C. C. van der Horst,Peter J. Hutchinson,Sander M. J. van Kuijk,Annalisa L. Liberti,David K. Menon,Cornelia W. E. Hoedemaekers,Bart Depreitere,Geert Meyfroidt,Ari Ercole,Marcel J. H. Aries,Peter Smielewski
DOI: https://doi.org/10.1007/s12028-024-02168-y
2024-12-05
Neurocritical Care
Abstract:The 'CPPopt-Guided Therapy: Assessment of Target Effectiveness' (COGiTATE) randomised controlled trial demonstrated the feasibility and safety of targeting an automated cerebral perfusion pressure (CPP) tailored to optimize cerebrovascular autoregulation (CPPopt) in patients with traumatic brain injury (TBI) requiring intracranial pressure management. The average values of the autoregulation index known as the pressure reactivity index (PRx) were not different between the intervention (CPP target = CPPopt) and control (CPP target = 60–70 mmHg) groups of the trial. This secondary analysis was performed to investigate whether: (1) in the intervention group, PRx was closer to PRxopt (PRx at CPPopt) values, indicating a more preserved reactivity, as opposed to in the control group; (2) in the intervention group, patients experienced lower hourly PRx when CPP was close to the CPPopt-based target.
clinical neurology,critical care medicine
What problem does this paper attempt to address?